5
Venmax Drugs & Pharmaceuticals
VENMAXDRUGSPHARMACEUTICALSLTD NSE
Venmax Drugs & Pharmaceuticals
HealthcareNSE: VENMAXDRUGSPHARMACEUTICALSLTD BSE: 531015 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹22.64 Cr
Volatility
Moderate
P/E Ratio
76.9
EBITDA
₹0.30 Cr
Return on Equity
1.76%
Debt to Equity
0.02
Book Value
₹14.37
52W High
₹31.49
52W Low
₹13.52
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company is almost debt free.
- Stock is trading at 1.17 times its book value
- Debtor days have improved from 247 to 65.1 days.
Weaknesses
2- Promoter holding has decreased over last quarter: -3.34%
- Promoter holding is low: 10.5%
Growth Rate
Revenue Growth
332% higher than
3Y
Net Income Growth
—
Cash Flow Change
-380% lower than
3Y
ROE
-833% lower than
3Y
ROCE
-712% lower than
3Y
EBITDA Margin (Avg.)
-937% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0.1 | 0.17 | 0.2 | 0.33 | 1.21 | 1.32 | 1.55 | 3.94 | 2.48 |
| Expenses | 0.03 | 0.03 | 0.01 | 0.04 | 0.12 | 0.47 | 0.69 | 0.57 | 1.17 | 1.27 | 1.58 | 3.92 | 2.36 |
| Operating Profit | -0.03 | -0.03 | -0.01 | -0.04 | -0.02 | -0.3 | -0.49 | -0.24 | 0.04 | 0.05 | -0.03 | 0.02 | 0.12 |
| OPM % | — | — | — | — | -20% | -176.47% | -245% | -72.73% | 3.31% | 3.79% | -1.94% | 0.51% | 4.84% |
| Other Income | 0.05 | 0 | 0.05 | 0.1 | 0.03 | 0 | 0 | 1.02 | 0 | 0 | 0.07 | 0.09 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0.02 | -0.03 | 0.04 | 0.06 | 0.01 | -0.3 | -0.49 | 0.78 | 0.04 | 0.05 | 0.04 | 0.11 | 0.12 |
| Tax % | 0% | 0% | 25% | 16.67% | 0% | 0% | 0% | 0% | 0% | 40% | 25% | 0% | 0% |
| Net Profit | 0.02 | -0.03 | 0.03 | 0.05 | 0.01 | -0.3 | -0.5 | 0.78 | 0.04 | 0.02 | 0.03 | 0.11 | 0.12 |
| EPS in Rs | 0.04 | -0.06 | 0.06 | 0.1 | 0.02 | -0.57 | -0.95 | 1.49 | 0.08 | 0.02 | 0.04 | 0.09 | 0.1 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.43 | 1.93 | 0.26 | 0 | 0.15 | 0.47 | 0.17 | 0 | 0 | 0 | 0.81 | 8.02 | 9.29 |
| Expenses | 2.54 | 2.07 | 0.88 | 0.23 | 0.38 | 0.72 | 0.5 | 0.12 | 0.19 | 0.11 | 1.87 | 7.9 | 9.13 |
| Operating Profit | -0.11 | -0.14 | -0.62 | -0.23 | -0.23 | -0.25 | -0.33 | -0.12 | -0.19 | -0.11 | -1.06 | 0.12 | 0.16 |
| OPM % | -4.53% | -7.25% | -238.46% | — | -153.33% | -53.19% | -194.12% | — | — | — | -130.86% | 1.5% | 1.72% |
| Other Income | 0 | 0 | -0.72 | 0 | 0 | 0 | 0.18 | 1.98 | 0.42 | 0.2 | 1.05 | 0.16 | 0.16 |
| Interest | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 |
| PBT | -0.11 | -0.14 | -1.34 | -0.24 | -0.24 | -0.26 | -0.16 | 1.85 | 0.22 | 0.08 | -0.02 | 0.28 | 0.32 |
| Tax % | -36.36% | 0% | 0% | 0% | 0% | 3.85% | 0% | 0% | 0% | 25% | 0% | 10.71% | — |
| Net Profit | -0.08 | -0.14 | -1.34 | -0.24 | -0.24 | -0.27 | -0.16 | 1.85 | 0.23 | 0.06 | -0.01 | 0.25 | 0.28 |
| EPS in Rs | -0.15 | -0.27 | -2.56 | -0.46 | -0.46 | -0.52 | -0.31 | 3.53 | 0.44 | 0.11 | -0.02 | 0.22 | 0.25 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 11.58 |
| Reserves | -4.9 | -5.04 | -7.11 | -7.35 | -7.59 | -7.86 | -8.03 | -6.18 | -5.95 | -5.89 | -0.83 | 2.53 |
| Borrowings | 1.5 | 1.72 | 1.85 | 2.04 | 2.24 | 2.52 | 2.33 | 0.35 | 0.35 | 0.35 | 0.05 | 0.33 |
| Other Liabilities | 1.85 | 0.68 | 0.16 | 0.14 | 0.44 | 0.56 | 0.76 | 0.8 | 0.57 | 0.38 | 0.71 | 1.76 |
| Total Liabilities | 3.69 | 2.6 | 0.14 | 0.07 | 0.33 | 0.46 | 0.3 | 0.21 | 0.21 | 0.08 | 5.17 | 16.2 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0.11 | 0.1 | 0.09 | 0.08 | 0.07 | 0.07 | 0.04 | 0.04 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 3.68 | 2.59 | 0.14 | 0.07 | 0.22 | 0.36 | 0.21 | 0.13 | 0.14 | 0.01 | 5.13 | 16.16 |
| Total Assets | 3.69 | 2.6 | 0.14 | 0.07 | 0.33 | 0.46 | 0.3 | 0.21 | 0.21 | 0.08 | 5.17 | 16.2 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -0.1 | -0.19 | -1.06 | -0.26 | -0.05 | -0.28 | 0.26 | 1.91 | 0 | 0 | -2.29 | -11 |
| Investing | 0 | 0 | 0.01 | 0 | -0.11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing | 0.1 | 0.22 | 1.02 | 0.26 | 0.16 | 0.28 | -0.19 | -1.98 | 0 | 0 | 4.77 | 9.74 |
| Net Cash Flow | 0 | 0.03 | -0.03 | 0 | 0 | 0 | 0.07 | -0.07 | 0 | 0 | 2.48 | -1.26 |
| Free Cash Flow | -0.1 | -0.19 | -1.05 | -0.26 | -0.17 | -0.28 | 0.26 | 1.91 | 0 | 0 | -2.29 | -11 |
| CFO/OP | 127 | 136 | 171 | 113 | 22 | 112 | -79 | -1,592 | 0 | -18 | 216 | -9,142 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 21.03 | 129 | 0 | — | 0 | 31.06 | 85.88 | — | — | — | 428 | 65.08 |
| Inventory Days | 225 | 0 | 0 | — | 446 | 251 | 0 | — | — | — | 27.72 | 50.14 |
| Days Payable | 252 | — | — | — | 1,257 | 456 | — | — | — | — | 291 | 84.23 |
| Cash Conversion Cycle | -5.04 | 129 | 0 | — | -811 | -174 | 85.88 | — | — | — | 165 | 30.99 |
| Working Capital Days | -3 | 5.67 | -2,723 | — | -5,986 | -2,112 | -6,334 | — | — | — | 874 | 588 |
| ROCE % | -6.01% | -7.45% | -52.63% | — | — | — | — | — | — | — | -0.96% | 2.96% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Venmax Drugs & Pharmaceuticals insights
62 extracted metrics + investor summaries across FY09–FY26.
Documents
1
Board Meeting Intimation for Audited Standalone Financial Results Of The Company For The Quarter And Year Ended March 31, 2026.
6 May - Board meeting on May 14, 2026 to approve audited FY26 financial results; trading window closed till May 16. 6 May - Board meeting on May 14, 2026 to approve audited FY26 financial results; trading window closed till May 16.
2
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended March 31, 2026. 14 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended March 31, 2026.
3
Compliances-Reg.24(A)-Annual Secretarial Compliance
14 Apr - Venmax Drugs says Annual Secretarial Compliance Report not applicable for year ended 31.03.2026. 14 Apr - Venmax Drugs says Annual Secretarial Compliance Report not applicable for year ended 31.03.2026.
4
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
14 Apr - Venmax confirms it does not qualify as a Large Corporate as of 31 March 2026. 14 Apr - Venmax confirms it does not qualify as a Large Corporate as of 31 March 2026.
5
Regulation 31(4) - SAST Disclosure
6 Apr - Promoters confirmed no encumbrance on their shares for FY2026 under SEBI SAST. 6 Apr - Promoters confirmed no encumbrance on their shares for FY2026 under SEBI SAST.
Frequently Asked Questions about Venmax Drugs & Pharmaceuticals
What does Venmax Drugs & Pharmaceuticals Ltd do?
Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services[1]
Where is Venmax Drugs & Pharmaceuticals Ltd (531015) listed?
Venmax Drugs & Pharmaceuticals Ltd trades as VENMAXDRUGSPHARMACEUTICALSLTD on the NSE and under code 531015 on the BSE.
Which sector does Venmax Drugs & Pharmaceuticals Ltd belong to?
Venmax Drugs & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Venmax Drugs & Pharmaceuticals Ltd?
Venmax Drugs & Pharmaceuticals Ltd has a market capitalisation of ₹22.64 Cr, which places it in the Small Cap band.
What is the PE ratio of Venmax Drugs & Pharmaceuticals Ltd?
Venmax Drugs & Pharmaceuticals Ltd trades at a PE ratio of 76.90, against a book value of ₹14.37 per share.
What is the 52-week high and low of Venmax Drugs & Pharmaceuticals Ltd?
Over the last 52 weeks Venmax Drugs & Pharmaceuticals Ltd has traded between ₹13.52 and ₹31.49.
What is the Return on Equity (ROE) of Venmax Drugs & Pharmaceuticals Ltd?
Venmax Drugs & Pharmaceuticals Ltd reported a return on equity of 1.76%. Its debt-to-equity ratio is 0.02.
Company Information
Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services[1]
Website venmaxdrugs.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531015.md for Venmax Drugs & Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.